Phuturdex › Diseases › Rectal neoplasm
Drugs in development · updated 30 October 2026
Rectal neoplasm: drugs in development
As of 30 October 2026 there are 149 active clinical trials (recruiting or ongoing, phases I–III) on 131 drugs for rectal neoplasm. 61 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
Sorted by most advanced phase and number of active trials. Showing 40 of 61 drugs.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| CapecitabineXeloda, Capectitabine Tablets | II–III | 47 | NCT05610163 |
| OxaliplatinOxaliplatine, Oxaliplain | II–III | 31 | NCT05610163 |
| Fluorouracil5-Fluorouracil, Adrucil | II–III | 16 | NCT05610163 |
| Bevacizumabavastin, MVASI | III | 13 | NCT06997497 |
| LeucovorinFolinic acid, l-leucovorin | II–III | 13 | NCT05610163 |
| CetuximabErbitux | III | 11 | NCT06997497 |
| IrinotecanOnivyde, CPT-11 | II–III | 9 | NCT05610163 |
| TislelizumabTisleizumab, Tiselizumab | II–III | 9 | NCT06443671 |
| DostarlimabTSR-042, Jemperli® | III | 4 | NCT07740720 |
| EncorafenibBraftovi® | III | 4 | NCT04607421 |
| AtezolizumabTecentriq, MPDL3280A | III | 3 | NCT05482516 |
| FruquintinibFruquinitinib, Fruzaqla® | II–III | 3 | NCT06443671 |
| AdagrasibMRTX849, Krazati® | III | 1 | NCT04793958 |
| LevoleucovorinLevofolinate, Levofolinic Acid | III | 1 | NCT06997497 |
| SildenafilViagra, Liqrev® | III | 1 | NCT06123156 |
Sorted by most advanced phase and number of active trials. Showing 15 of 70 drugs.
All 131 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Anus neoplasm 28 drugs
- Uterine cervix neoplasm 224 drugs
- Vulvar neoplasm 32 drugs
- Head and neck squamous cell carcinoma 321 drugs
- Vaginal neoplasm 21 drugs
- Penile neoplasm 26 drugs
- Cholangiocarcinoma 136 drugs
- Anal Canal Carcinoma 8 drugs
- Endometrial neoplasm 298 drugs
- Mesothelioma 54 drugs
- Thyroid neoplasm 99 drugs
- Metastasis 493 drugs
Broader categories
- Digestive System Diseases 36 drugs
- Digestive system neoplasm 37 drugs
- Gastrointestinal disease 22 drugs
- Intestinal disease 15 drugs
- Rectal disease 9 drugs
- Intestinal neoplasm 16 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D012004 “Rectal Neoplasms”.